Logo image of SNSE

SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Fundamental Analysis

NASDAQ:SNSE - Nasdaq - US81728A1088 - Common Stock - Currency: USD

0.3  -0.04 (-10.58%)

After market: 0.2906 -0.01 (-3.13%)

Fundamental Rating

1

SNSE gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. The financial health of SNSE is average, but there are quite some concerns on its profitability. SNSE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SNSE had negative earnings in the past year.
In the past year SNSE has reported a negative cash flow from operations.
SNSE had negative earnings in each of the past 5 years.
SNSE had a negative operating cash flow in each of the past 5 years.
SNSE Yearly Net Income VS EBIT VS OCF VS FCFSNSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -75.85%, SNSE is not doing good in the industry: 67.80% of the companies in the same industry are doing better.
The Return On Equity of SNSE (-90.75%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -75.85%
ROE -90.75%
ROIC N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
SNSE Yearly ROA, ROE, ROICSNSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

SNSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNSE Yearly Profit, Operating, Gross MarginsSNSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for SNSE has been increased compared to 1 year ago.
SNSE has less shares outstanding than it did 5 years ago.
The debt/assets ratio for SNSE has been reduced compared to a year ago.
SNSE Yearly Shares OutstandingSNSE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SNSE Yearly Total Debt VS Total AssetsSNSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SNSE has an Altman-Z score of -10.68. This is a bad value and indicates that SNSE is not financially healthy and even has some risk of bankruptcy.
SNSE has a Altman-Z score of -10.68. This is in the lower half of the industry: SNSE underperforms 75.13% of its industry peers.
SNSE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SNSE (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.68
ROIC/WACCN/A
WACCN/A
SNSE Yearly LT Debt VS Equity VS FCFSNSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

SNSE has a Current Ratio of 6.82. This indicates that SNSE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.82, SNSE is in the better half of the industry, outperforming 66.01% of the companies in the same industry.
SNSE has a Quick Ratio of 6.82. This indicates that SNSE is financially healthy and has no problem in meeting its short term obligations.
SNSE has a Quick ratio of 6.82. This is in the better half of the industry: SNSE outperforms 66.19% of its industry peers.
Industry RankSector Rank
Current Ratio 6.82
Quick Ratio 6.82
SNSE Yearly Current Assets VS Current LiabilitesSNSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

0

3. Growth

3.1 Past

SNSE shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.96%.
EPS 1Y (TTM)4.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 7.68% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.31%
EPS Next 2Y23.14%
EPS Next 3Y11.32%
EPS Next 5Y7.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNSE Yearly Revenue VS EstimatesSNSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M
SNSE Yearly EPS VS EstimatesSNSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SNSE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNSE Price Earnings VS Forward Price EarningsSNSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNSE Per share dataSNSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.14%
EPS Next 3Y11.32%

More info and screens

0

5. Dividend

5.1 Amount

SNSE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENSEI BIOTHERAPEUTICS INC

NASDAQ:SNSE (6/13/2025, 8:00:02 PM)

After market: 0.2906 -0.01 (-3.13%)

0.3

-0.04 (-10.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners7.69%
Inst Owner Change-17.8%
Ins Owners2.11%
Ins Owner Change0%
Market Cap7.56M
Analysts88
Price Target4.08 (1260%)
Short Float %1.19%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.19%
Min EPS beat(2)-18.53%
Max EPS beat(2)-9.85%
EPS beat(4)2
Avg EPS beat(4)-3.63%
Min EPS beat(4)-18.53%
Max EPS beat(4)9.02%
EPS beat(8)5
Avg EPS beat(8)0.36%
EPS beat(12)8
Avg EPS beat(12)1.08%
EPS beat(16)9
Avg EPS beat(16)-1.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.03%
EPS NQ rev (1m)-75%
EPS NQ rev (3m)-115.38%
EPS NY rev (1m)-28.48%
EPS NY rev (3m)-19.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS1.27
TBVpS1.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.85%
ROE -90.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.82
Quick Ratio 6.82
Altman-Z -10.68
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.02%
Cap/Depr(5y)183.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.62%
EPS Next Y18.31%
EPS Next 2Y23.14%
EPS Next 3Y11.32%
EPS Next 5Y7.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.94%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.66%
OCF growth 3YN/A
OCF growth 5YN/A